The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Links

 

Gene Review

Pyy  -  peptide YY (mapped)

Rattus norvegicus

Synonyms: GHYY, PYY, Peptide YY, Peptide tyrosine tyrosine, RATGHYY, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Pyy

  • To investigate whether the stimulatory influence of IGF-I is exerted at the level of gene transcription, rat PYY 5'-upstream sequences (-2800/+37 bp, -770/+37 bp, -127/+37 bp) fused to the firefly luciferase (luc) reporter gene were transfected into rat pheochromocytoma cells (PC12) and luc activity measured after IGF-I treatment [1].
  • At the pressor dose (0.6 nmol/kg) but not subpressor dose (0.2 nmol/kg), the increase in blood pressure induced by stimulation of the sympathetic outflow (ST: 0.3 Hz, 50 V, 1 min) was attenuated by PYY (by 40%), whereas ST-evoked tachycardia was reduced by NPY (by 35%) [2].
  • (5) In stably transfected adenocarcinoma cells expressing Y(1) or Y(1)(C337S) receptors, PYY inhibited anion secretion stimulated by vasoactive intestinal peptide (VIP; measured as short-circuit current, I(SC)) with similar potency (EC(50): 26-53 nM) [3].
  • The following peptides, NPY, PYY, [Leu31, Pro34]-NPY (a Y1 receptor agonist) and NPY13-36 (a Y2 receptor agonist) were administered intravenously at the dose of 40 micrograms/100 g body weight [4].
  • Suppression of peptide YY-induced hyperphagia by terbutaline [5].
 

Psychiatry related information on Pyy

  • NPY's discriminative stimulus properties were compared to those of two doses of Peptide YY (PYY) and 24 and 48 h of food deprivation, conditions which also increase feeding [6].
  • Injection of PYY directly into the PVN, in doses ranging from 7.8 to 235 pmol/0.3 microliters, caused a strong, dose-dependent stimulation of feeding behavior, as well as a small stimulation of drinking behavior, in satiated rats [7].
  • An i.c.v. dose of peptide YY produced a different effect from NPY, with increase in the motor activities of both fed and fasted patterns [8].
  • RESULTS: PYY (1, 3, and 10 micrograms/10 microL) strongly induced feeding behavior in a dose-dependent manner in sated rats [9].
 

High impact information on Pyy

  • Using a chemical detection method, a search for previously unknown peptides that possess the C-terminal amide structure in extracts of brain and intestine was carried out and a number of novel neuropeptides and hormonal peptides, designated neuropeptide Y, PHI, peptide YY, galanin and neuropeptide K were isolated [10].
  • BACKGROUND & AIMS: The cellular target for peptide YY (PYY) inhibition of gastric acid secretion is unknown [11].
  • The aim of this study was to determine whether PYY inhibits histamine release from isolated enterochromaffin-like (ECL) cells by stimulation of a selective Y receptor [11].
  • Peptide YY inhibition of rat gastric enterochromaffin-like cell function [11].
  • The inhibitory action of PYY and related peptides on gastrin-stimulated histamine release and calcium signaling was eliminated by pretreatment with 200 ng/mL pertussis toxin [11].
 

Chemical compound and disease context of Pyy

 

Biological context of Pyy

 

Anatomical context of Pyy

 

Associations of Pyy with chemical compounds

 

Physical interactions of Pyy

  • 125I-NPY binding sites are found in similar areas, but relative levels of NPY binding and PYY binding differ regionally, suggesting differences in sites labeled by the two ligands [16].
 

Regulatory relationships of Pyy

  • Here we show that this is also true for the rat CNS, by demonstrating expression of peptide YY (PYY) mRNA in brainstem neurons distinct from those neurons that express NPY mRNA [21].
  • Intracisternal injection of NPY and PYY (0.1-0.5 microgram) did not influence the acid response to pentagastrin but blocked CRF-induced inhibition of pentagastrin-stimulated acid secretion [22].
  • NPY and PYY inhibited both the slow 5-HT1A receptor-mediated IPSP and the alpha 1-adrenoceptor-mediated slow EPSP while not affecting the fast, amino acid-mediated synaptic responses [23].
  • Functionally, neuropeptide Y and peptide YY dose-dependently triggered arginine 8-vasopressin and oxytocin release from perfused isolated terminals, and potentiated the arginine-8-vasopressin release induced by depolarization [24].
  • Peptide YY is an ileocolonic peptide known to inhibit postprandial and cholecystokinin-induced pancreatic exocrine secretion [25].
 

Other interactions of Pyy

  • IGF-I increased PYY (-127/+37 bp)-luc activity in a time- and dose-dependent fashion [1].
  • Moreover, the GG, BB12, and inulin mixture increased the concentrations of NPY and PYY for adult rats [26].
  • Spinal and peripheral modulation of gastric acid secretion and arterial pressure by neuropeptide Y, peptide YY, and pancreatic polypeptide in rats [13].
  • NPY and PYY act as signal factors of the absorptive phase function as antagonists of the postabsorptive glucose regulatory hormones glucagon and noradrenaline [27].
  • The PYY probe hybridized with two populations of neurons in the brainstem: one dispersed along the midline in the rostral medulla and another in the lateral caudal medulla (A1 region) [21].
 

Analytical, diagnostic and therapeutic context of Pyy

References

  1. Insulin-like growth factor I increases rat peptide YY promoter activity through Sp1 binding sites. Wang, G., Leiter, A.B., Englander, E.W., Greeley, G.H. Endocrinology (2004) [Pubmed]
  2. Neuropeptide Y and peptide YY mediate nonadrenergic vasoconstriction and modulate sympathetic responses in rats. Zukowska-Grojec, Z., Haass, M., Bayorh, M.A. Regul. Pept. (1986) [Pubmed]
  3. Control of signalling efficacy by palmitoylation of the rat Y1 receptor. Holliday, N.D., Cox, H.M. Br. J. Pharmacol. (2003) [Pubmed]
  4. Role of neuropeptide Y in the regulation of tyrosine hydroxylase gene expression in rat adrenal glands. Hong, M., Li, S., Fournier, A., St-Pierre, S., Pelletier, G. Neuroendocrinology (1995) [Pubmed]
  5. Suppression of peptide YY-induced hyperphagia by terbutaline. Hagan, M.M., Moss, D.E. Pharmacol. Biochem. Behav. (1993) [Pubmed]
  6. The discriminative stimulus effects of neuropeptide Y. Jewett, D.C., Schaal, D.W., Cleary, J., Thompson, T., Levine, A.S. Brain Res. (1991) [Pubmed]
  7. Paraventricular nucleus injections of peptide YY and neuropeptide Y preferentially enhance carbohydrate ingestion. Stanley, B.G., Daniel, D.R., Chin, A.S., Leibowitz, S.F. Peptides (1985) [Pubmed]
  8. Neuropeptide Y induces fasted pattern of duodenal motility via Y(2) receptors in conscious fed rats. Fujimiya, M., Itoh, E., Kihara, N., Yamamoto, I., Fujimura, M., Inui, A. Am. J. Physiol. Gastrointest. Liver Physiol. (2000) [Pubmed]
  9. Thioperamide, a histamine H3 receptor antagonist, powerfully suppresses peptide YY-induced food intake in rats. Itoh, E., Fujimiya, M., Inui, A. Biol. Psychiatry (1999) [Pubmed]
  10. Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Tatemoto, K., Efendić, S., Mutt, V., Makk, G., Feistner, G.J., Barchas, J.D. Nature (1986) [Pubmed]
  11. Peptide YY inhibition of rat gastric enterochromaffin-like cell function. Zeng, N., Walsh, J.H., Kang, T., Wu, S.V., Sachs, G. Gastroenterology (1997) [Pubmed]
  12. Reduction of gut hypoplasia and cachexia in tumor-bearing rats maintained on total parenteral nutrition and treated with peptide YY and clenbuterol. Chance, W.T., Zhang, X., Zuo, L., Balasubramaniam, A. Nutrition (Burbank, Los Angeles County, Calif.) (1998) [Pubmed]
  13. Spinal and peripheral modulation of gastric acid secretion and arterial pressure by neuropeptide Y, peptide YY, and pancreatic polypeptide in rats. Wager-Pagé, S.A., Rosenbaum, G., Veale, W.L., Davison, J.S. Peptides (1993) [Pubmed]
  14. Peptide YY. Structure of the precursor and expression in exocrine pancreas. Leiter, A.B., Toder, A., Wolfe, H.J., Taylor, I.L., Cooperman, S., Mandel, G., Goodman, R.H. J. Biol. Chem. (1987) [Pubmed]
  15. Solubilization and affinity purification of the Y2 receptor for neuropeptide Y and peptide YY from rabbit kidney. Sheikh, S.P., Hansen, A.P., Williams, J.A. J. Biol. Chem. (1991) [Pubmed]
  16. Neuropeptide Y receptor binding sites in rat brain: differential autoradiographic localizations with 125I-peptide YY and 125I-neuropeptide Y imply receptor heterogeneity. Lynch, D.R., Walker, M.W., Miller, R.J., Snyder, S.H. J. Neurosci. (1989) [Pubmed]
  17. Neuropeptide Y modulates neurotransmitter release and Ca2+ currents in rat sensory neurons. Walker, M.W., Ewald, D.A., Perney, T.M., Miller, R.J. J. Neurosci. (1988) [Pubmed]
  18. Pathways and receptors involved in peptide YY induced contraction of rat proximal colonic muscle in vitro. Ferrier, L., Segain, J.P., Pacaud, P., Cherbut, C., Loirand, G., Galmiche, J.P., Blottière, H.M. Gut (2000) [Pubmed]
  19. Neuropeptide Y and peptide YY inhibit excitatory synaptic transmission in the rat dorsal motor nucleus of the vagus. Browning, K.N., Travagli, R.A. J. Physiol. (Lond.) (2003) [Pubmed]
  20. Peptide-YY and neuropeptide-Y inhibit vasoactive intestinal peptide-stimulated adenosine 3',5'-monophosphate production in rat small intestine: structural requirements of peptides for interacting with peptide-YY-preferring receptors. Servin, A.L., Rouyer-Fessard, C., Balasubramaniam, A., Saint Pierre, S., Laburthe, M. Endocrinology (1989) [Pubmed]
  21. Differential expression of mRNAs for neuropeptide Y-related peptides in rat nervous tissues: possible evolutionary conservation. Pieribone, V.A., Brodin, L., Friberg, K., Dahlstrand, J., Söderberg, C., Larhammar, D., Hökfelt, T. J. Neurosci. (1992) [Pubmed]
  22. Reversal by NPY, PYY and 3-36 molecular forms of NPY and PYY of intracisternal CRF-induced inhibition of gastric acid secretion in rats. Gué, M., Junien, J.L., Reeve, J.R., Rivier, J., Grandt, D., Taché, Y. Br. J. Pharmacol. (1996) [Pubmed]
  23. Neuropeptide Y selectively inhibits slow synaptic potentials in rat dorsal raphe nucleus in vitro by a presynaptic action. Kombian, S.B., Colmers, W.F. J. Neurosci. (1992) [Pubmed]
  24. Neuropeptide Y2 receptors on nerve endings from the rat neurohypophysis regulate vasopressin and oxytocin release. Sheikh, S.P., Feldthus, N., Orkild, H., Göke, R., McGregor, G.P., Turner, D., Møller, M., Stuenkel, E.L. Neuroscience (1998) [Pubmed]
  25. Inhibition of unstimulated exocrine pancreatic secretion by peptide YY in the rat. Robinson, D.C., Rudnicki, M., Tito, J.M., Gold, M.S. World journal of surgery. (1996) [Pubmed]
  26. Effect on Components of the Intestinal Microflora and Plasma Neuropeptide Levels of Feeding Lactobacillus delbrueckii, Bifidobacterium lactis, and Inulin to Adult and Elderly Rats. Lesniewska, V., Rowland, I., Cani, P.D., Neyrinck, A.M., Delzenne, N.M., Naughton, P.J. Appl. Environ. Microbiol. (2006) [Pubmed]
  27. Neuropeptide Y and peptide YY, but not pancreatic polypeptide, substance P, cholecystokinin and gastric inhibitory polypeptide, inhibit the glucagon- and noradrenaline-dependent increase in glucose output in rat liver. Lüers, C., Gardemann, A., Miura, H., Jungermann, K. European journal of gastroenterology & hepatology. (2000) [Pubmed]
  28. Neuropeptide Y and galanin binding sites in rat and monkey lumbar dorsal root ganglia and spinal cord and effect of peripheral axotomy. Zhang, X., Ji, R.R., Nilsson, S., Villar, M., Ubink, R., Ju, G., Wiesenfeld-Hallin, Z., Hökfelt, T. Eur. J. Neurosci. (1995) [Pubmed]
 
WikiGenes - Universities